Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-3705 extension study in methylmalonic acidemia
NCT05295433Phase 2Recruiting
- Sponsor
- Moderna Inc
- Start
- Mar 2022
- Primary completion
- Apr 2034
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 6
01
Overview
A Phase 2 trial of mRNA-3705 in methylmalonic acidemia (MMA), sponsored by Moderna Inc. Started Mar 2022; status: recruiting.
02
Drugs
mRNA-3705
03
Conditions
methylmalonic acidemia (MMA)
Beyond the preview
Go deeper on NCT05295433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05295433.